Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748477 | 0.81 | NT5E (0.30) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21999123 | 0.81 | HSP90AA1 (0.35) | DHFRCA2CHKA | |
| SCHEMBL7318102 | 0.78 | ADORA1 (0.39) | — | |
| SCHEMBL21999122 | 0.77 | MAP3K12 (0.32) | — | |
| SCHEMBL24117652 | 0.74 | TLR7 (0.32) | — | |
| SCHEMBL2174181 | 0.72 | PDE4B (0.33) | — | |
| SCHEMBL21929809 | 0.71 | FFAR1 (0.30) | — | |
| SCHEMBL19748809 | 0.71 | PTGS2 (0.42) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL8240075 | 0.69 | ADORA2A (0.55) | — | |
| SCHEMBL15743431 | 0.68 | PIK3CA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250243206-A1 | CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| CN-120040450-A | Crystalline forms of a phosphoinositide 3 kinase (PI 3K) inhibitor | 因赛特公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-113677683-B | Crystalline forms of a phosphoinositide 3 kinase (PI 3K) inhibitor | 因赛特公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12173006-B2 | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor | INCYTE CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| CN-118063470-A | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4338801-A2 | CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR | Incyte Corporation (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| WO-2019079469-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079469-A1 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| WO-2017223414-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | GABRA1 1683/4885GABRG2 643/4885GABRB3 1078/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | GABRA1 983/4885GABRG2 501/4885GABRB3 1648/4885 |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | GABRA1 1237/4885GABRG2 470/4885GABRB3 663/4885 |
| US-20190152975-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | GABRA1 1237/4885GABRG2 470/4885GABRB3 663/4885 |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | PIK3CA, PIK3CG, PIK3CD | GABRA1 1052/4885GABRG2 1141/4885GABRB3 2263/4885 |
| US-12173006-B2 | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor | PIK3CA, PIK3CD, PIK3CG | GABRA1 4198/4885GABRG2 4226/4885GABRB3 4589/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | GABRA1 1490/4885GABRG2 861/4885GABRB3 1036/4885 |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | GABRA1 1490/4885GABRG2 861/4885GABRB3 1036/4885 |
| US-20250243206-A1 | CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR | PIK3CA, PIK3CD, PIK3CG | GABRA1 4198/4885GABRG2 4226/4885GABRB3 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.